Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
- Journal
- PubMed
In The Last Decade
doi.org/w84703030 →Countries where authors are citing Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
This map shows the geographic impact of Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. more than expected).
Fields of papers citing Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
This network shows the impact of Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel..
About Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
This paper, published in 2002, received 504 indexed citations . Written by Nuhad K. Ibrahim, Neil Desai, Sewa S. Legha, Patrick Soon‐Shiong, Richard L. Theriault, Edgardo Rivera, Bita Esmaeli, Sigrid Ring, Agop Y. Bedikian and Gabriel N. Hortobágyi covering the research area of Oncology, Hematology and Biomaterials. It is primarily cited by scholars working on Oncology (299 citations), Biomaterials (207 citations) and Molecular Biology (127 citations). Published in PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/w84703030.